Who are Verona Pharma's investors?

Verona Pharma's investors include Access Biotechnology, Aisling Capital, Andera Partners, Foresite Capital, Frazier Life Sciences, Sofinnova Partners, venBio Partners, Vivo Capital and 2 more.

How much funding has Verona Pharma raised?

Verona Pharma has disclosed $244.7M raised across 2 rounds.

Where is Verona Pharma headquartered?

Verona Pharma is headquartered in London.

Verona Pharma

London · United Kingdom corporation · 10 known investors

veronapharma.com ↗

Verona Pharma develops treatments for chronic lung conditions. As of October 2025, it and its subsidiaries are part of Merck & Co., Inc.

BiotechHealthtech

Founders & leadership

Jan-Anders KarlssonExecutive

Peter SpargoExecutive

Patrick HumphreyNamed on SEC filing

Ken CunninghamNamed on SEC filing

Kenneth NewmanNamed on SEC filing

Anders UllmanNamed on SEC filing

Board

David EbsworthBoard director

Investors · 10

Access BiotechnologyNew York City

Aisling CapitalNew York

Andera PartnersParis

Foresite CapitalLarkspur

Frazier Life SciencesPalo Alto

Sofinnova PartnersParis · $540K – $27M

venBio PartnersSan Francisco

Vivo CapitalPalo Alto · $10M – $50M

AbingworthreportedLondon · $15M – $30Mvia Andrew Sinclair · board

Vivo PandareportedPalo Alto

Reported raises · per SEC filings

Form D private placements

$244.7M disclosed across 2 rounds · 2016–2020

▶$200.2MraisedJul 2020 · 43 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Andrew SinclairDirector
Mahendra ShahDirector
Rishi GuptaDirector
David EbsworthDirector
Mark W. HahnExecutive Officer
Kathleen RickardExecutive Officer
Anders UllmanDirector
Claire PollExecutive Officer
Martin EdwardsDirector
Ken CunninghamDirector
David ZaccardelliExecutive Officer, Director
Vikas SinhaDirector

Offering amount: $200.2M
Amount sold: $200.2M
Sales commissions: $12M
Placement agents: JEFFERIES LLC, CANACCORD GENUITY LLC, WEDBUSH SECURITIES INC., BTIG, LLC
First sale: Jul 2020
Incorporated: Corporation, United Kingdom
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$44.5MraisedJul 2016 · 8 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Jan-Anders KarlssonExecutive Officer, Director
David EbsworthDirector
Patrick HumphreyDirector
Peter SpargoExecutive Officer
Ken CunninghamDirector
Kenneth NewmanExecutive Officer
Anders UllmanDirector

Offering amount: $44.5M
Amount sold: $44.5M
Minimum investment: $421K
Sales commissions: $2.9M
Placement agents: MTS SECURITIES, LLC
First sale: Jun 2016
Incorporated: Corporation, United Kingdom
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Research and Medical Grants | Verona Pharmaveronapharma.com · May 2024

Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription - Verona Pharmaveronapharma.com · Jul 2020

Frequently asked questions

What does Verona Pharma do?: Verona Pharma develops treatments for chronic lung conditions. As of October 2025, it and its subsidiaries are part of Merck & Co., Inc.
Who are Verona Pharma's investors?: Verona Pharma's investors include Access Biotechnology, Aisling Capital, Andera Partners, Foresite Capital, Frazier Life Sciences, Sofinnova Partners, venBio Partners, Vivo Capital and 2 more.
How much funding has Verona Pharma raised?: Verona Pharma has disclosed $244.7M raised across 2 rounds.
Where is Verona Pharma headquartered?: Verona Pharma is headquartered in London.